Dr. Theodossis Theodossiou

Institute for Cancer Research, Oslo University Hospital

Photodynamic Treatment of Cancer

Dr. Theodossis Theodossiou discusses his team’s cutting-edge research into curing cancer with photodynamic therapy (PDT). PDT is an exciting anti-cancer treatment, currently used clinically. It works by using light, a photo-activatable drug and oxygen to kill cancer, where the specificity of the treatment depends on which wavelength of light is applied. In this video, Dr. Theodossiou describes how his team are working to improve the efficiency and accuracy of PDT through a variety of methods.

LIKE 1


Dr. Theodossis Theodossiou
Cell Biology Cell Analysis Cell Culture

Dr. Theodossis Theodossiou

Biography

Theodossiou is a team leader, senior researcher in project LUMIBLAST sponsored by FET open Horizon 2020 More

Dr. Theodossis Theodossiou

Institute for Cancer Research, Oslo University Hospital

Dr. Theodossis Theodossiou is a senior researcher, and project group leader in the area "Protonics" at the Institue for Cancer Research, Oslo University Hospital. His reasearch group is carrying out research on the use of ionising and non-ionising radiation as cancer therapeutics The main aim of the PROTONICs team is the combinatory use of ionising radiation-based therapies like Proton Therapy and/or Neutron Capture Therapy, together with light based therapies, like Photodynamic Therapy (PDT) or Photochemical Internalisation to achieve a breakthrough anticancer strategy. This multifaceted effort also employs the use of cancer-specific nanoparticles, the use of innovative intracellular light sources for PDT, the interplay between various reactive oxygen species and the use of the cancer cells’ own devices to defeat them. The team further specialises in mitochondrial bioenergetics, the effect of various assaults (chemical, photochemical or radiative) on the mitochondrial respiration and the consequent interplay between respiratory and glycolytic cell metabolism. Our niche is the design and exploration of novel high risk – high gain experimental therapeutics, including not previously envisaged or anticipated strategies. Our activities are currently supported by local (Helse Sor Ost) as well as European funding (Future and Emerging Technologies and Euronanomed).